Business
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma Ended the quarter with ...
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"Strategic focus on exploratory investigator-initiated clinical studies with institutional partners","length":98,"tagName":"p"},{"type":"text","content":"Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma","length":124,"tagName":"p"},{"type":"text","content":"Ended the quarter with $5.2 million of cash to fund operations  ","length":83,"tagName":"p"},{"type":"text","content":"FRAMINGHAM, MA / ACCESS Newswire / May 14, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2025.","length":342,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced that its collaboration partner, PeriNess Ltd., entered into a Clinical Study Agreement to advance development of DNase platform for the treatment of relapsed/refractory osteosarcoma and Ewing sarcoma; and","length":214,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued pursuit of other strategic collaborations to advance the Company's technology.","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":306,"olType":false},{"type":"text","content":""We remain focused on engaging with our strategic partners to participate in a series of exploratory studies to evaluate our systemic DNase I in combination with immunotherapy, chemotherapy, and radiotherapy in various oncology indications where there remains significant unmet need to advance our development programs forward. These partnerships allow us to advance our technology toward the clinic while utilizing our resources efficiently and minimizing our internal investment. Additionally, this development strategy opens up valuable opportunities to continue expanding our growing body of positive preclinical data that supports the use of DNase I across several cancer indications," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.","length":797,"tagName":"p"},{"type":"text","content":"Xenetic continues to advance its DNase-based techno...